摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

番泻叶提取物 | 85085-71-8

中文名称
番泻叶提取物
中文别名
——
英文名称
sennoside A
英文别名
Senna;(9R)-9-[(9R)-2-carboxy-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracen-9-yl]-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-carboxylic acid
番泻叶提取物化学式
CAS
85085-71-8
化学式
C42H38O20
mdl
MFCD00151527
分子量
862.752
InChiKey
IPQVTOJGNYVQEO-KGFNBKMBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 物理描述:
    Senna (powdered) is a yellow-brown powder with a slight odor and taste. (NTP, 1992)
  • 熔点:
    220-243°C
  • 溶解度:
    less than 1 mg/mL at 66° F (NTP, 1992)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    62
  • 可旋转键数:
    9
  • 环数:
    8.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    348
  • 氢给体数:
    12
  • 氢受体数:
    20

ADMET

毒理性
  • 肝毒性
在推荐剂量下短时间内使用番泻叶与少数副作用有关,其中大多数副作用都是轻微且短暂的,与其泻药作用有关。然而,长期和高剂量使用番泻叶已有不良事件报道,包括多起临床上明显的肝损伤病例。肝损伤的出现时间通常在使用3到5个月后,血清酶升高的模式是肝细胞型。肝损伤通常是轻到中度的严重程度,并在停药后迅速缓解。至少在一个实例中,再次接触导致了肝损伤的快速复发。已发表的病例中未出现免疫过敏特征和自身免疫标记。 此外,一种常见的相关植物,通常被称为咖啡番泻叶或豆寇,已被联系到许多急性、严重毒性事件,包括脑病、肌病和肝功能障碍。在印度北部的Uttar Pradesh,每年通常在9月到11月之间,会发生原因不明的“肝-肌-脑病”爆发。调查最终确定摄入西番泻叶是可能的原因,通常发生在吃这种常见开花杂草的叶或豆荚的儿童中。虽然西番泻叶也被用来泡茶,但摄入的量是最小的。在儿童中,偶尔在成人中,病情表现急剧,伴有恶心、呕吐、震颤、异常和暴力行为、做鬼脸和自残,随后是昏迷,此时血清转氨酶和胆红素水平通常会升高。在严重的情况下,肝损伤是进行性的,血清氨和INR水平升高,患者出现昏迷、惊厥和状态性癫痫,对治疗无反应。尸检显示肝细胞坏死和胆汁淤积。摄入西番泻叶的动物也会出现类似的症状和损伤模式。这种综合征是否与罕见情况下归因于典型番泻叶(作为泻药使用的狭叶番泻或尖叶番泻)的肝损伤有相似的病理机制尚不清楚。 可能性评分:D(可能是临床上明显肝损伤的罕见原因)。
Use of senna in the recommended doses for a limited period of time has been associated with few side effects, most of which are mild and transient and related to its laxative action. With longer term and higher dose use of senna, however, adverse events have been described including several cases of clinically apparent liver injury. The time to onset of liver injury was usually after 3 to 5 months of use, and the pattern of serum enzyme elevations was hepatocellular. The liver injury was usually mild-to-moderate in severity and resolved rapidly with discontinuation. In at least one instance, reexposure led to rapid recurrence of liver injury. Immunoallergic features and autoimmune markers were not present in the published cases. In addition, a related plant commonly known as coffee senna or Cassia orientalis has been linked to many instances of acute, severe toxicity with encephalopathy, myopathy and hepatic dysfunction. Outbreaks of “hepato-myo-encephopathy” of unknown cause among children occurred yearly in Uttar Pradesh, India typically between September and November. Investigation eventually identified Cassia occidentalis ingestion as the probable cause, typically occurring in children who eat the leaves or pods of the common flowering weed. While Cassia occidentalis has also been used to prepare tea, the amount ingested was minimal. In children, and rarely in adults, the presentation was precipitous with nausea, vomiting, tremor, abnormal and violent behavior, grimacing and self-mutilation followed by stupor and coma at which time serum aminotransferase and bilirubin levels were typically elevated. In severe instances, the liver injury was progressive, serum ammonia and INR levels rose and patients developed coma, convulsions and status epilepticus that was unresponsive to therapy. Autopsies revealed hepatic necrosis and cholestasis. A similar pattern of symptoms and injury occurs in animals that consume Cassia occidentalis. Whether this syndrome has a similar pathogenesis to the rare instance of hepatic injury attributed to typical senna (Cassia acutifolia or angustifolio) that is used as a laxative is unknown. Likelihood score: D (possible rare cause of clinically apparent liver injury).
来源:LiverTox
毒理性
  • 在妊娠和哺乳期间的影响
使用期间的总结:尽管一份早期的非对照报告使用一种老式的大黄产品发现哺乳婴儿的腹泻频率增加,但使用现代大黄产品的几个对照研究发现对婴儿没有影响。通常剂量的大黄在哺乳期间是可以接受的。 ◉ 对哺乳婴儿的影响:在分娩后第5天给予3.6毫升大黄流浸膏后,观察到10名婴儿中有6名对肠道有泻药作用。 在另一项观察性研究中,148名在分娩后第3天服用两茶匙Senokot(相当于700毫克大黄豆荚)的母亲中,没有观察到哺乳婴儿出现腹泻的情况。 50名在分娩后第一天的母亲服用了相当于450毫克大黄豆荚的大黄。如果需要,在随后的几天里会给予额外的剂量。他们哺乳的婴儿中没有注意到明显异常的大便,尽管所有婴儿也接受了补充喂养。 在一项随机、非盲的研究中,35位母亲在分娩后立即开始每天服用一次含有总共14毫克标准化大黄提取物的片剂,持续2周。37名哺乳婴儿中有6名据报道出现腹泻,这比研究中其他非吸收性泻药的比例要高。 16名妇女服用了含有24毫克大黄苷的大黄粉800毫克。他们哺乳的婴儿中没有异常的大便。 一项随机、双盲试验比较了商业大黄片剂(Senokot)的剂量为每天两次,每次2片(14毫克大黄苷a和b),共8剂,从分娩后第一天开始,与安慰剂进行比较。研究中,126名妇女在服用大黄的同时哺乳她们的婴儿,而155名对照组的母亲哺乳她们的婴儿。在活动组和对照组中,有大便稀疏或腹泻的婴儿百分比没有差异。 20名产后母亲在分娩后第2至4天服用了一种含有车前子种子(欧车前)和大黄的大黄,相当于每天15毫克大黄苷a和b。在11名哺乳的婴儿中,没有一个有大便稀疏。 ◉ 对泌乳和母乳的影响:截至修订日期,没有找到相关的已发布信息。
◉ Summary of Use during Lactation:Although an early uncontrolled report using an old senna product found increased frequency of diarrhea in breastfed infants, several controlled studies using modern senna products found no effect on the infant. Usual doses of senna are acceptable to use during breastfeeding. ◉ Effects in Breastfed Infants:After administration of 3.6 mL of senna fluidextract on day 5 postpartum, a laxative effect on the bowels was observed in 6 of 10 infants. In another observational study, no cases of diarrhea were observed among the breastfed infants of 148 mothers who received 2 teaspoonfuls of Senokot (equivalent to 700 mg of senna pod) on day 3 postpartum. Fifty mothers who were in the first day postpartum received senna equal to 450 mg of senna pod. Additional doses were given on subsequent days if needed. None of their breastfed infants were noted to have any markedly abnormal stools, although all of the infants also received supplemental feedings. In a randomized, nonblinded study, 35 mothers were given tablets containing a total of 14 mg of standardized senna extract once daily for 2 weeks starting in the immediate postpartum period. Six of the 37 breastfed infants were reported to have diarrhea which was a higher percentage than with other nonabsorbable laxatives in the study. Sixteen women were given 800 mg of powdered senna containing 24 mg of sennosides. None of their breastfed infants had any abnormal stools. A randomized, double-blind trial compared commercial senna tablets (Senokot) in a dose of 2 tablets (14 mg sennosides a and b) twice daily for 8 doses started on the first day postpartum to placebo. Of the women in the study, 126 breastfed their infants and took senna while 155 control mothers breastfed their infants. There was no difference in the percentages of infants in the active and control groups with loose stools or diarrhea. Twenty postpartum mothers were given a laxative containing plantango seeds (psyllium) and senna equivalent to 15 mg of sennosides a and b daily on days 2 to 4 postpartum. Of the 11 infants who were breastfed, none had any loose stools. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.
来源:Drugs and Lactation Database (LactMed)

制备方法与用途

番泻叶提取物简介 产品名称

【产品名称】 番泻叶提取物
【英文名称】 Folium Sennae Extract
【拉丁名称】 Cassia angustifolia, Cassia senna

提取来源

本品为豆科植物狭叶番泻的干燥小叶。

化学成分

叶中主要成分是番泻叶苷A+B,包括芦荟大黄素和大黄酸-8-葡萄糖甙;约10%的粘胶质、丹宁酸和类黄酮等。

颜色性状

【颜色性状】 棕黄色粉末

产品功效

具有清热行滞通便、利尿的功效。有一定抗菌功能,临床尚可用于急性胰腺炎、菌痢、流行性出血热、胆囊炎、产后回乳等。适用于药品、保健品等领域。

功效详解
  • 泻下作用:番泻叶的药效以双蒽酮甙类如番泻甙A作用最强,蒽醍甙次之,游离蒽醍可能经消化道氧化,故作用较弱;结合型的甙类有保护作用,在大肠时经细菌或酶分解成甙元,刺激大肠,增加张力和蠕动,并减少水分吸收而致泻。
  • 抗真菌:25%水浸剂用试管法,对奥杜盎小孢子菌、星形奴卡菌有抑制作用;
  • 止血:番泻叶总蒽醍甙200mg/kg腹腔注射,对小鼠毛细管法有一定止血作用;
  • 毒性:番泻叶甙腹腔注射,对小鼠的LD50为1.141g/kg。

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    番泻叶提取物 在 rat feces suspension 作用下, 以 为溶剂, 反应 9.0h, 生成 大黄酸-9-蒽酮
    参考文献:
    名称:
    Metabolism of sennosides by intestinal flora.
    摘要:
    通过研究大鼠肠道内容物和粪便中番泻苷的代谢过程,揭示了其主要的代谢途径,并发现这些途径与之前基于从人类肠道分离出的各个菌株所产生的代谢物而提出的途径大相径庭。番泻苷A通过肠道内容物和粪便中的β-葡萄糖苷酶逐步水解,先形成番泻双蒽酮A-8-单葡萄糖苷,再转化为番泻双蒽酮A;番泻苷B也以类似方式通过番泻双蒽酮B-8-单葡萄糖苷转化为番泻双蒽酮B。在实验条件下,所得代谢物番泻双蒽酮A和B可相互转化,并进一步被还原,可能通过肠道细菌细胞膜上的还原酶,生成大黄泻素蒽酮,这是大黄根茎和番泻叶的泻下活性成分。
    DOI:
    10.1248/cpb.30.1338
点击查看最新优质反应信息

文献信息

  • Preventives/remedies for urinary disturbance
    申请人:Ishichi Yuji
    公开号:US20070099986A1
    公开(公告)日:2007-05-03
    A compound represented by the formula: wherein Ar represents a group represented by the formula: (wherein Y represents methylene or an oxygen atom, R 1 represents aminosulfonyl, C 1-6 alkylaminosulfonyl, C 1-6 alkylcarbonylamino or C 1-6 alkylsulfonylamino, R 2 represents a hydrogen atom or C 1-6 alkyl, R 3 represents C 1-6 alkyl, and R 4 represents a hydrogen atom or C 1-6 alkyl); X represents a carbonyl group, or a methylene group which may be substituted with a hydroxy group; and L represents an optionally substituted C 4-5 alkylene group, or a salt thereof is provided.
    一个由以下式表示的化合物:其中Ar代表以下式表示的基团:(其中Y代表亚甲基或氧原子,R1代表氨基磺酰基,C1-6烷基氨基磺酰基,C1-6烷基羰基氨基或C1-6烷基磺酰基氨基,R2代表氢原子或C1-6烷基,R3代表C1-6烷基,R4代表氢原子或C1-6烷基);X代表羰基,或者可能被羟基取代的亚甲基;L代表可选择取代的C4-5烷基烯基,或其盐。
  • [EN] A CO-AMORPHOUS FORM OF A SUBSTANCE AND A DIPEPTIDE<br/>[FR] FORME CO-AMORPHE D'UNE SUBSTANCE ET D'UN DIPEPTIDE
    申请人:UNIV COPENHAGEN
    公开号:WO2018113891A1
    公开(公告)日:2018-06-28
    The present invention relates to co-amorphous formulation of a substance and a dipeptide. The present invention also relates to pharmaceutical, cosmetic or veterinary compositions comprising the co-amorphous formulation as well as to methods for preparing and using the co-amorphous formulation.
    本发明涉及一种物质和二肽的共同非晶形态配方。本发明还涉及包含该共同非晶形态配方的药用、化妆品或兽医组合物,以及制备和使用该共同非晶形态配方的方法。
  • Agents and crystals for improving excretory potency of urinary bladder
    申请人:——
    公开号:US20020177593A1
    公开(公告)日:2002-11-28
    Agents for improving potentcy of the urinary bladder which comprises an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action. Particularly, crystals of a tricyclic, condensed, heterocyclic derivative are provided, which possess an excellent action to inhibit acetylcholine esterase and an action to improve the excretory potency of urinary bladder. As an example, crystals of of 8-[3-[1-[(3-fluorophenyl)-methyl]-4-piperidinyl]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one or a salt thereof and pharmaceutical compositions containing them are disclosed.
    改善膀胱功能的药剂,包括一种非卡巴酯类胺化合物,具有乙酰胆碱酯酶抑制作用。特别地,提供了一种三环、紧凑、杂环衍生物的晶体,具有优异的抑制乙酰胆碱酯酶作用和改善膀胱排泄功能的作用。例如,揭示了8-[3-[1-[(3-氟苯基)-甲基]-4-哌啶基]-1-氧代丙基]-1,2,5,6-四氢-4H-吡咯烷[3,2,1-ij]-喹啉-4-酮或其盐和含有它们的药物组合物。
  • Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism
    申请人:Lawrence Daniel A.
    公开号:US20100137194A1
    公开(公告)日:2010-06-03
    The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.
    本发明涉及纤溶酶原激活剂-1(PAI-1)抑制剂化合物及其在治疗任何与升高的PAI-1相关的疾病或病状中的应用。本发明包括但不限于使用这些化合物来调节脂质代谢并治疗与升高的PAI-1、胆固醇或脂质水平相关的病症。
  • Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
    申请人:Babul Najib
    公开号:US20120065221A1
    公开(公告)日:2012-03-15
    The present invention is directed to oral, therapeutically effective extended release pharmaceutical compositions of 3-hydroxy-N-methylmorphinan, including delayed onset, extended release dosage forms and the use thereof.
    本发明涉及口服、治疗有效的3-羟基-N-甲基吗啡酮的延迟作用、延长释放药物组成物,包括延迟起效、延长释放剂型及其使用。
查看更多

同类化合物

齐斯托醌 黄决明素 马普替林杂质E(N-甲基马普替林) 马普替林杂质D 马普替林 颜料黄199 颜料黄147 颜料黄123 颜料黄108 颜料红89 颜料红85 颜料红251 颜料红177 颜料紫27 顺式-1-(9-蒽基)-2-硝基乙烯 阿美蒽醌 阳离子蓝3RL 长蠕孢素 镁蒽四氢呋喃络合物 镁蒽 锈色洋地黄醌醇 锂钠2-[[4-[[3-[(4-氨基-9,10-二氧代-3-磺基-1-蒽基)氨基]-2,2-二甲基-丙基]氨基]-6-氯-1,3,5-三嗪-2-基]氨基]苯-1,4-二磺酸酯 锂胭脂红 链蠕孢素 铷离子载体I 铝洋红 铂(2+)二氯化1-({2-[(2-氨基乙基)氨基]乙基}氨基)蒽-9,10-二酮(1:1) 钾6,11-二氧代-6,11-二氢-1H-蒽并[1,2-d][1,2,3]三唑-4-磺酸酯 钠6,11-二氧代-6,11-二氢-1H-蒽并[1,2-d][1,2,3]三唑-4-磺酸酯 钠4-({4-[乙酰基(乙基)氨基]苯基}氨基)-1-氨基-9,10-二氧代-9,10-二氢-2-蒽磺酸酯 钠2-[(4-氨基-9,10-二氧代-3-磺基-9,10-二氢-1-蒽基)氨基]-4-{[2-(磺基氧基)乙基]磺酰基}苯甲酸酯 钠1-氨基-9,10-二氢-4-[[4-(1,1-二甲基乙基)-2-甲基苯基]氨基]-9,10-二氧代蒽-2-磺酸盐 钠1-氨基-4-[(3-{[(4-甲基苯基)磺酰基]氨基}苯基)氨基]-9,10-二氧代-9,10-二氢-2-蒽磺酸酯 钠1-氨基-4-[(3,4-二甲基苯基)氨基]-9,10-二氧代-9,10-二氢-2-蒽磺酸酯 钠1-氨基-4-(1,3-苯并噻唑-2-基硫基)-9,10-二氧代蒽-2-磺酸盐 醌茜隐色体 醌茜素 酸性蓝127:1 酸性紫48 酸性紫43 酸性兰62 酸性兰25 酸性兰182 酸性兰140 酸性兰138 酸性兰 129 透明蓝R 透明蓝AP 透明红FBL 透明紫BS